- Home
- SONN vs ARTL Comparison
SONN vs ARTL Comparison
Compare SONN & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONN
- ARTL
- Stock Information
- Founded
- SONN N/A
- ARTL 2011
- Country
- SONN United States
- ARTL United States
- Employees
- SONN N/A
- ARTL N/A
- Industry
- SONN Biotechnology: Pharmaceutical Preparations
- ARTL Biotechnology: Pharmaceutical Preparations
- Sector
- SONN Health Care
- ARTL Health Care
- Exchange
- SONN Nasdaq
- ARTL Nasdaq
- Market Cap
- SONN 3.8M
- ARTL 3.1M
- IPO Year
- SONN N/A
- ARTL N/A
- Fundamental
- Price
- SONN $1.17
- ARTL $1.05
- Analyst Decision
- SONN Strong Buy
- ARTL Strong Buy
- Analyst Count
- SONN 1
- ARTL 2
- Target Price
- SONN $20.00
- ARTL $5.50
- AVG Volume (30 Days)
- SONN 35.4K
- ARTL 47.0K
- Earning Date
- SONN 05-13-2025
- ARTL 05-13-2025
- Dividend Yield
- SONN N/A
- ARTL N/A
- EPS Growth
- SONN N/A
- ARTL N/A
- EPS
- SONN N/A
- ARTL N/A
- Revenue
- SONN $1,000,000.00
- ARTL N/A
- Revenue This Year
- SONN $5,376.22
- ARTL N/A
- Revenue Next Year
- SONN N/A
- ARTL N/A
- P/E Ratio
- SONN N/A
- ARTL N/A
- Revenue Growth
- SONN 978.39
- ARTL N/A
- 52 Week Low
- SONN $1.08
- ARTL $0.82
- 52 Week High
- SONN $16.00
- ARTL $1.55
- Technical
- Relative Strength Index (RSI)
- SONN 41.48
- ARTL 58.54
- Support Level
- SONN $1.08
- ARTL $0.90
- Resistance Level
- SONN $1.21
- ARTL $1.02
- Average True Range (ATR)
- SONN 0.08
- ARTL 0.07
- MACD
- SONN -0.01
- ARTL 0.01
- Stochastic Oscillator
- SONN 30.00
- ARTL 62.18
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
About ARTL Artelo Biosciences Inc.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.